Randomized, Double-Blind, Phase III Study of TAS-102 Versus Placebo in Asian Patients With Metastatic Colorectal Cancer Refractory or Intolerable to Standard Chemotherapies

Trial Profile

Randomized, Double-Blind, Phase III Study of TAS-102 Versus Placebo in Asian Patients With Metastatic Colorectal Cancer Refractory or Intolerable to Standard Chemotherapies

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TERRA
  • Sponsors Taiho Pharmaceutical Company
  • Most Recent Events

    • 05 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
    • 05 Feb 2017 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2017.
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top